Apellis Pharmaceuticals (APLS) concentration risks

The company's concentration profile is defined by two reinforcing high-share exposures: a single commercial product and a narrow distributor base funneling substantially all of its revenue. The company's prospects depend substantially upon the commercial success of SYFOVRE, a high-share product concentration with a mixed character — it is structural in that the company has deliberately built its commercial operations around this asset, but it also carries dependency-like risk because there is no revenue diversification across multiple approved products. A clinical safety signal, reimbursement setback, or competitive displacement targeting SYFOVRE would have a direct and potentially decisive impact on the income statement. Layered on top of the product concentration is a high-share customer dependency: sales to a small number of distributors account for substantially all gross revenue related to SYFOVRE. This is a dependency-character exposure — the company relies on a narrow channel to move its sole commercial product, meaning that a disruption in any major distributor relationship could interrupt revenue flow even if SYFOVRE demand remains intact. Together, these two exposures compound each other: the entire revenue base flows through a handful of distributors to a single product. There is no geographic, pipeline, or counterparty diversification disclosed to partially offset this concentration. For investors, the key watch items are SYFOVRE prescription trends, payer coverage dynamics, and the stability of the key distributor relationships.

For the engine’s reasoning on APLS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.